The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment.
- Author:
Ming Hui LI
1
;
Lu ZHANG
1
;
Xiao Jing QU
1
;
Yao LU
1
;
Gei SHEN
1
;
Zhen Zhen LI
1
;
Shu Ling WU
1
;
Ru Yu LIU
1
;
Min CHANG
1
;
Lei Ping HU
1
;
Wen Hao HUA
2
;
Shu Jing SONG
2
;
Gang WAN
1
;
Yao XIE
1
Author Information
- Publication Type:Journal Article
- Keywords: Chronic hepatitis B; HBeAg; HBsAg loss; Pegylated interferon alpha-2a
- MeSH: Adolescent; Adult; Antiviral Agents; therapeutic use; Child; Child, Preschool; DNA, Viral; blood; Drug Administration Schedule; Female; Hepatitis B Surface Antigens; blood; Hepatitis B e Antigens; blood; Hepatitis B, Chronic; blood; drug therapy; Humans; Interferon-alpha; administration & dosage; therapeutic use; Male; Middle Aged; Polyethylene Glycols; administration & dosage; therapeutic use; Recombinant Proteins; administration & dosage; therapeutic use; Retrospective Studies; Young Adult
- From: Biomedical and Environmental Sciences 2017;30(3):177-184
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo explore the predictive value of baseline HBsAg level and early response for HBsAg loss in patients with HBeAg-positive chronic hepatitis B during pegylated interferon alpha-2a treatment.
METHODSA total of 121 patients with HBeAg-positive chronic hepatitis B who achieved HBsAg loss were enrolled; all patients were treated with PEG-IFNα-2a 180 μg/week. Serum HBV DNA and serological indicators (HBsAg, anti-HBs, HBeAg, and anti-HBe) were determined before and every 3 months during treatment.
RESULTSThe median treatment time for HBsAg loss was 84 weeks (7-273 weeks), and 74.38% (90 cases) of the patients needed extended treatment (> 48 weeks). The correlation between baseline HBsAg levels and the treatment time of HBsAg loss was significant (B = 14.465, t = 2.342, P = 0.021). Baseline HBsAg levels together with the decline range of HBsAg at 24 weeks significantly correlated with the treatment time of HBsAg loss (B = 29.862, t = 4.890, P = 0.000 and B = 27.993, t = 27.993, P = 0.005).
CONCLUSIONBaseline HBsAg levels and extended therapy are critical steps toward HBsAg loss. Baseline HBsAg levels together with early response determined the treatment time of HBsAg loss in patients with HBeAg-positive chronic hepatitis B during pegylated interferon alpha-2a treatment.
